PD-L1 expression has been shown to correlate with ICI benefits in several cancer types [224,225], and intertumoral PD-L1 expression is associated with response in patients with HCC who were treated with nivolumab [226]. The gene discussed is CD274; the disease is hepatocellular carcinoma.